Luc Friboulet
Villejuif, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 78 publications
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026
Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 17, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
Journal: NPJ precision oncology
Published: February 13, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 15, 2025
Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 02, 2025
BRAF Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With BRAFV600E-Mutated Lung Adenocarcinoma.
Journal: JCO precision oncology
Published: April 16, 2025
Comprehensive molecular landscape of anal squamous cell carcinoma: analysis of tissue and liquid biopsies from 1844 patients.
Journal: NPJ precision oncology
Published: April 15, 2025
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study.
Journal: NPJ precision oncology
Published: November 26, 2024
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 05, 2024
Author Correction: The genomic and transcriptomic landscape of metastastic urothelial cancer.
Journal: Nature communications
Published: October 31, 2024
Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms.
Journal: JTO clinical and research reports
Published: August 29, 2024
Last Updated: 09/26/2026